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Significance of the Study
• Pharmacotherapy in older patients with a limited life expectancy should avoid unnecessary polyphar-
macy and focus on symptom control. This study showed a small reduction in the use of commonly 
prescribed preventive medications. Medications could be reviewed to optimize polypharmacy.
DOI: 10.1159/000499692
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Abstract
Objective: Older people approaching the end of life are at a 
high risk for adverse drug reactions. Approaching the end of 
life should change the therapeutic aims, triggering a reduc-
tion in the number of drugs. The main aim of this study is to 
describe the preventive and symptomatic drug treatments 
prescribed to patients discharged with a limited life expec-
tancy from internal medicine and geriatric wards. The sec-
ondary aim was to describe the potentially severe drug-drug 
interactions (DDI). Materials and Methods: We analyzed 
Registry of Polytherapies Societa Italiana di Medicina Interna 
(REPOSI), a network of internal medicine and geriatric wards, 
to describe the drug therapy of patients discharged with a 
limited life expectancy. Results: The study sample com-
prised 55 patients discharged with a limited life expectancy. 
Patients with at least 1 preventive medication that could be 
considered for deprescription at the end of life were signifi-
cantly fewer from admission to discharge (n = 30; 54.5% vs. 
n = 21; 38.2%; p = 0.02). Angiotensin-converting enzyme in-
hibitors, angiotensin II receptor blockers, calcium channel 
blockers, lipid-lowering drugs, and clonidine were the most 
frequent potentially avoidable medications prescribed at 
discharge, followed by xanthine oxidase inhibitors and 
drugs to prevent fractures. Thirty-seven (67.3%) patients 
were also exposed to at least 1 potentially severe DDI at dis-
charge. Conclusion: Hospital discharge is associated with a 
small reduction in the use of commonly prescribed preven-
tive medications in patients discharged with a limited life 
expectancy. Cardiovascular drugs are the most frequent po-
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tentially avoidable preventive medications. A consensus 
framework or shared criteria for potentially inappropriate 
medication in elderly patients with limited life expectancy 
could be useful to further improve drug prescription.
© 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
The end of life is the preterminal phase of a person’s 
decline towards death and normally involves accumulat-
ing health problems over a period of weeks to months, 
with failing homeostasis that is irreversible and inexora-
bly leads to death [1]. Older people approaching the end 
of life are at a high risk for adverse drug reactions result-
ing from polypharmacy, declining organ function, co-
morbidity, malnutrition, cachexia, and changes in body 
composition [2]. As a consequence, approaching the end 
of life should shift the therapeutic aims, triggering a re-
duction in the number of drugs, but this is not the usual 
practice [3–5]. 
The aim of pharmacotherapy in the rising numbers of 
end-of-life older people should be to avoid polypharmacy 
and focus on controlling symptoms rather than prolong-
ing life [1, 2]. Although polypharmacy is very common 
among older end-of-life patients, with their need to re-
lieve symptoms, disease-related problems, and quality of 
life [6–8], it may also be a major risk factor for inappro-
priate prescribing and potentially severe drug-drug inter-
actions (DDI) [2, 9, 10]. In this circumstance, drugs for 
the prevention of secondary diseases are of no value if the 
time to therapeutic benefit exceeds the probable life ex-
pectancy and should be discouraged. However, the few 
studies that have examined drug therapy in patients at the 
end of life have found that about half of them continued 
to take ineffective and unnecessary medication for the 
prevention or treatment of chronic diseases [11], al-
though the potential for harm can be expected to out-
weigh any benefit in view of the limited life expectancy [6, 
12]. Statins, antihypertensives and bisphosphonates are 
frequently used in patients with a terminal disease and 
advanced disability, although the real benefits are un-
known because their safety and efficacy have been dem-
onstrated for a young general population but evidence 
supporting their utility at the end of life is limited [12–
14].
No study has examined the prescription of internal 
and geriatric hospital specialists to patients with a limited 
life expectancy. The main aim of this study was to de-
scribe the preventive and symptomatic drug treatments 
prescribed to patients discharged with a limited life ex-
pectancy from internal medicine and geriatric wards. The 
secondary aim was to describe the potentially severe DDI. 
Materials and Methods
Data Collection
The Registry of Polytherapies Societa Italiana di Medicina In-
terna (REPOSI) is a collaborative, independent initiative of the 
Italian Society of Internal Medicine (SIMI), the Istituto di Ricerche 
Farmacologiche Mario Negri IRCCS, and the IRCCS Ca’ Granda 
Maggiore Policlinico Hospital Foundation. The registry was set up 
in 2008 by a network of internal medicine and geriatric wards in 
order to collect information on elderly hospital in-patients with 
multimorbidities receiving multiple drugs. The first run of data 
collection was between January and December 2008, and the sec-
ond, third, and fourth runs as well as ongoing runs took place be-
tween January and December 2010, 2012, 2014, and 2016, respec-
tively. To ensure an unselected population of elderly patients ad-
mitted to internal medicine and geriatric wards, the first 5 patients 
admitted to the wards participating in this study during 4-week 
periods 3 months apart were consecutively recruited if they were 
65 years old or older. Participation was voluntary and all patients 
gave signed informed consent. Data collection complied fully with 
Italian law on personal data protection and this study was ap-
proved by the ethics committees of each ward participating in RE-
POSI. 
The attending physicians completed a standardized web-based 
case report form, recording sociodemographic details and the di-
agnosis and drug treatment at admission, during the hospital stay, 
and at discharge. From the second REPOSI runs we collected the 
following additional information for a short-term follow-up in or-
der to improve the quality of the data: main laboratory parameters, 
comorbidity according to the Cumulative Illness Rating Scale 
(CIRS), basic activities of daily living, cognitive impairment, de-
pression, and clinical events during the hospital stay. Patients were 
followed for 3 months after discharge via a telephone interview in 
order to collect information on new diagnoses, hospital readmis-
sions, drug regimens, adverse events, basic activities of daily living, 
and mortality. 
To describe the drug therapy of patients discharged with a lim-
ited life expectancy, we considered eligible for analysis all patients 
discharged in “critical condition,” defined as a high risk of short-
term mortality (at 3 months) on the basis of the clinical evaluation. 
Analysis of each patient’s drug therapy at admission reflects drugs 
prescribed by general practitioners for patients who lived at home, 
or physicians in nursing homes for those in an institution; drug 
therapy at discharge referred to prescriptions by hospital internists 
or geriatricians. Patients transferred to palliative care wards, 
though potentially terminally ill, were excluded because the drug 
therapy at discharge was not collected.
Classification of Drug Therapies 
The drugs prescribed at admission and discharge were divided 
into the following 3 main classes according to their preventive or 
symptomatic effects: (1) potentially avoidable preventive medica-
tions, i.e., drugs that usually have no place in the end-of-life patient 
because the time to benefit is clearly shorter than the life expec-
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tancy; (b) medications of uncertain appropriateness, i.e., drugs 
that need a case-by-case evaluation because they could have a role 
in end-of-life patients but their real effectiveness is questionable 
on account of the short life expectancy; and (c) potentially appro-
priate treatments, i.e., drugs that provide symptomatic relief or 
that should be tapered slowly over several weeks or months in or-
der to avoid withdrawal symptoms, such as psychotropic drugs or 
proton pump inhibitors [15]. A geriatrician and a clinical pharma-
cologist separately analyzed drug prescriptions and resolved any 
discordances with a final round.
Statistical Analysis
The patients’ sociodemographic characteristics were compared 
using univariate analysis by χ2 tests for categorical variables and t 
tests or matched pair t tests for continuous variables. The McNe-
mar test was used to compare drug treatments at admission and 
discharge. p < 0.05 were considered statistically significant. Analy-
ses were done using JMP Pro 12 (SAS Institute Inc., Cary, USA). 
Results
The sample comprised 55 end-of-life patients recruit-
ed among the patients discharged by the internal medi-
cine and geriatric wards of REPOSI. Follow-up data were 
available for 30 of those discharged in critical conditions; 
27 (90%) died between discharge and the 3-month fol-
low-up, confirming their limited life expectancy. The 
main sociodemographic characteristics and diagnoses are 
reported in Table 1. Patients had high rates of comorbid-
ity and most of them suffered from cardiovascular dis-
eases. About 72% had a caregiver and most had cognitive 
impairment consistent with a diagnosis of dementia. Half 
of the patients had been admitted in the previous 6 months 
and were bedridden at discharge with pressure sores.
The mean number of drugs remained the same from 
admission to discharge (mean ± SD: 5.5 ± 3.6 and 5.5 ± 
3.4; p = 0.97). Table 2 lists the drugs that we considered 
as potentially avoidable preventive medications in end-
of-life patients, those of uncertain appropriateness, and 
those that were potentially appropriate. There were sig-
nificantly fewer patients with at least 1 preventive medi-
cation that could be considered for deprescription at the 
end of life from admission to discharge (p = 0.02). Angio-
tensin-converting-enzyme inhibitors, angiotensin recep-
tor blockers, calcium channel blockers, lipid-lowering 
drugs, and clonidine were the most frequent potentially 
avoidable cardiovascular medications prescribed at dis-
charge, followed by xanthine oxidase inhibitors and drugs 
to prevent fractures. Drugs for peptic ulcer and gastro-
esophageal reflux disease, analgesics, psychotropic drugs, 
and systemic corticosteroids were the potentially appro-
priate symptomatic medications maintained at discharge.
Patients exposed to at least 1 potentially severe DDI 
slightly increased between admission (31; 56.4%) and dis-
charge (37; 67.3%; p = 0.18); drugs that concomitantly 
increased the risk of QT prolongation and torsades de 
pointes, followed by those that increased the risk of bleed-
ing, were the most frequent potentially severe DDI (Table 
3).
Discussion
Identification of the end of life should bring about a sig-
nificant reduction in the number of daily drugs, but this 
was not observed in the present study. Hospital discharge 
was associated with only a small, though significant, reduc-
tion in the use of preventive medications that are com-
monly prescribed. However, these results could be further 
Table 1. Main characteristics and diagnosis of the 55 patients dis-
charged in critical condition
Characteristic Value
Age, years 80.8± 83
Female sex, % 43.6
Caregiver 38 (71.7)
Hospital admission in the previous 






Pressure sores 24 (66.7)
Systolic blood pressure 116.2±22.1
Diastolic blood pressure 67.1±12.4
Short Blessed Test 15.6±8.6
Barthel index 54.7±34.4
Geriatric depression scale 1.8±1.1




     Hypertension 41 (74.6)
     Heart failure 15 (27.3)
     Chronic renal failure 13 (23.6)
     Atrial fibrillation 14 (25.4)
     Cancer 23 (41.8)
     Diabetes 13 (23.6)
     Ischemic heart disease 14 (25.4)
     Chronic bronchitis 13 (23.6)
     Anemia 11 (20.0)
     Dementia 13 (23.6)
     Cachexia 1 (0.2)
Values are presented as means ± SD or numbers (%) unless 
otherwise stated.
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improved since in fact about 40% of patients were dis-
charged with avoidable medications. Cardiovascular drugs 
were the potentially avoidable preventive medications 
most frequently prescribed at admission that were partial-
ly reduced at discharge. Most cardiovascular drugs usually 
have no place in end-of-life patients because the time to 
benefit is clearly shorter than the life expectancy [2]; when 
prescribed to prevent diabetic nephropathy or reduce mor-
tality from heart failure angiotensin-converting-enzyme 
inhibitors, angiotensin receptor blockers, and calcium 
channel blockers (excluding diltiazem or verapamil) are of 
little value when a patient’s life expectancy is severely cur-
tailed as a result of other irreversible disorders. Similarly, 
lipid-lowering drugs are almost always inappropriate at 
the end of life. There were definite reductions in the pre-
scription of oral antidiabetics and xanthine oxidase inhib-
itors at discharge. Stopping these drugs is generally appro-
priate because the goals for managing diabetes change at 
the end of life since it is no longer important to prevent the 
long-term effects of hyperglycemia. Similarly, treating as-
ymptomatic hyperuricemia to prevent gout is clearly inap-
propriate [16] in the end-of-life patient.
Among the preventive medications of uncertain ap-
propriateness, the use of low-molecular-weight heparin 
increased at discharge while the proportion of patients 
treated with antiplatelet drugs decreased; these drugs 
could be useful in preventing thrombotic events, although 
they increase the risk of bleeding in older and frailer pa-
Patients
admission discharge
Potentially avoidable preventive medications
At least 1 30 (54.5) 21 (38.2)
Cardiovascular drugs
Omega-3 1 1
Statins 5 3 
Clonidine 3 3
ACE inhibitors or ARB 15 9 
Calcium channel blockers 10 4
Hematological agents
Iron – 1
Folic acid – 2
Antidiabetic agents
Oral antidiabetic 4 0
Other
Xanthine oxidase inhibitors 11 5 
Calcium carbonate 1 1
Cholecalciferol – 1
Preventive medications of uncertain appropriateness
At least 1 34 (61.8) 30 (54.5)
Hematological agents
Low-molecular-weight heparin 12 20 
Erythropoietin-stimulating agents 2 4 
Antiplatelets 18 7
Oral anticoagulants 4 4
Other








At least 1 50 (90.9) 47 (85.5)
Cardiovascular drugs 
High-ceiling diuretic 21 19 
β-Blockers 15 10 
Diltiazem 1 1 
Potassium-sparing diuretics 9 5 
Long-acting nitratesb 7 7 
Cardiac therapy 9 8 
Analgesics 11 17
Gastrointestinal drugs
Drug for peptic ulcer and GERD 35 36
Laxatives 3 4 
Prokinetics 2 3 
Psychotropic drugs
Antidepressantsc 7 5 





Systemic corticosteroids 10 20 
Antiasthmatics 11 8 
Antibiotics 8 16 
Alpha antagonists for BPH 5 4 
Testosterone 5α-reductase 
inhibitors 2 2
Antiepileptics 9 7 
Antifungals 1 4 
Antiparkinson 3 1
Thyroid therapy 6 5
Values are presented as numbers (%) or numbers. ACE, 
angiotensin-converting-enzyme; ARB, angiotensin II receptor 
antagonist; BPH, benign prostatic hypertrophy; GERD, gastro-
esophageal reflux disease. a  To relieve itching caused by partial 
biliary obstruction. b  Including nitroglycerin and isosorbide. 
c Including trazodone, venlafaxine, and duloxetine; p = 0.02.
Table 2. Main pharmacological treatment of patients discharged in critical condition
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tients who often fall. It is hard to assess the appropriate-
ness of these medications and a case-by-case evaluation is 
needed, although anticoagulants and antiplatelets were 
frequently involved in potentially severe DDI at dis-
charge, increasing the risk of adverse drug events. Be-
cause deprescribing must consider not only the risks of 
individual drugs but also the cumulative risk of DDI [17], 
the higher percentage of patients exposed to potentially 
severe DDI emphasizes the need for closer evaluation of 
drugs prescribed to end-of-life patients.
Our findings suggest that the review of drug medica-
tions, optimizing polypharmacy and deprescribing could 
be further improved in older adults discharged with a 
very limited life expectancy (e.g., less than 3 months). A 
consensus framework, or shared criteria with deprescrib-
ing guidelines for potentially inappropriate medication, 
could be useful in rationalizing drug therapy. Careful 
consideration of a patient’s life expectancy, the time to 
benefit of treatments, goals of care, and treatment targets 
for each drug (including those used for a long time before 
the end-of-life period) is important for recommending 
any rational framework for decision making [2, 5, 18]. 
There may be several reasons for physicians not con-
sidering the discontinuation of futile medications in pa-
tients with a limited life expectancy. Scant awareness, as 
well the reactions of patients or their relatives, seems to 
be an important factor [19]. Unexpectedly, patients may 
be more willing to stop unnecessary medications than 
their physicians believe, as observed in a study of older 
patients with multiple chronic morbidities who were fa-
vorable to discontinue medication in 90% of cases [20]. 
Emphasizing the positive aspects of stopping medicines, 
such as reducing the burden of taking pills, rather than 
insisting on the uselessness of continuation, may be a 
helpful approach [21] that physicians could emphasize in 
conversations with patients and relatives. 
The strength of this study is that this it analyzes how 
the hospital transition can be associated with changes in 
preventive and symptomatic medications by internal 
medicine and geriatric specialists for patients with a lim-
ited life expectancy.
This study has some limitations. First, REPOSI was not 
specifically designed to collect information about patients 
with a limited life expectancy and only those able to give 
written informed consent were enrolled, thus excluding 
those who were too frail to give consent. The sample of 
patients is very small, because we focused on patients in 
‘critical conditions’, so we could assess the use of preven-
tive or symptomatic drugs in patients with a limited life 
expectancy according to the clinical evaluation. 
Conclusion
Hospital discharge is associated with a small reduction 
in the use of commonly prescribed preventive medica-
tions in patients discharged with a limited life expectancy. 
Cardiovascular drugs are the most frequent potentially 
avoidable preventive medications. A consensus frame-
work or shared criteria for potentially inappropriate 
medication in elderly patients with a limited life expec-
tancy could help improve drug prescription.
Table 3. Most frequent potentially severe DDI
Drug class combination Potential adverse events Patients
admission discharge
Drugs associated with QT prolongation [22] Increased risk of QT prolongation and  
torsades de pointes
26 (47.3) 32 (58.2)
Anticoagulants or antiplatelets + antiplatelets or SSRI Increased risk of bleeding 10 (18.2) 11 (20.0)
Digoxin + high-ceiling diuretic Increased risk of digoxin toxicity 4 (7.3) 5 (9.1)
SSRI + opioid analgesic Increased risk of serotonin syndrome 3 (5.5) 1 (1.8)
Potassium-sparing diuretics + ACE inhibitors or
 potassium supplements or enoxaparine
Increased risk of hyperkalemia 2 (3.6) 4 (7.3)
Statin + inhibitor of hepatic metabolisma Increased risk of myopathy including 
rhabdomyolysis
2 (3.6) 2 (3.6)
Fluoroquinolones + systemic corticosteroid Increased risk of tendon rupture 2 (3.6) 1 (1.8)
Values are presented as numbers (%). SSRI, selective serotonin reuptake inhibitors; ACE, angiotensin converting enzyme.
a Ticagrelor.
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